- Home
- MEDP vs IPG Comparison
MEDP vs IPG Comparison
Compare MEDP & IPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- IPG
- Stock Information
- Founded
- MEDP 1992
- IPG 1902
- Country
- MEDP United States
- IPG United States
- Employees
- MEDP N/A
- IPG N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- IPG Advertising
- Sector
- MEDP Health Care
- IPG Consumer Discretionary
- Exchange
- MEDP Nasdaq
- IPG Nasdaq
- Market Cap
- MEDP 11.7B
- IPG N/A
- IPO Year
- MEDP 2016
- IPG N/A
- Fundamental
- Price
- MEDP $342.89
- IPG $32.06
- Analyst Decision
- MEDP Buy
- IPG Hold
- Analyst Count
- MEDP 10
- IPG 9
- Target Price
- MEDP $402.44
- IPG $32.83
- AVG Volume (30 Days)
- MEDP 385.5K
- IPG 3.9M
- Earning Date
- MEDP 10-21-2024
- IPG 10-22-2024
- Dividend Yield
- MEDP N/A
- IPG 4.12%
- EPS Growth
- MEDP 27.33
- IPG 12.66
- EPS
- MEDP 10.64
- IPG 2.71
- Revenue
- MEDP $2,030,048,000.00
- IPG $9,405,200,000.00
- Revenue This Year
- MEDP $15.81
- IPG $1.00
- Revenue Next Year
- MEDP $12.91
- IPG $1.50
- P/E Ratio
- MEDP $32.21
- IPG $11.83
- Revenue Growth
- MEDP 21.36
- IPG 0.57
- 52 Week Low
- MEDP $227.21
- IPG $27.20
- 52 Week High
- MEDP $459.77
- IPG $35.17
- Technical
- Relative Strength Index (RSI)
- MEDP 46.60
- IPG 63.51
- Support Level
- MEDP $331.32
- IPG $31.23
- Resistance Level
- MEDP $357.10
- IPG $32.00
- Average True Range (ATR)
- MEDP 8.70
- IPG 0.48
- MACD
- MEDP 2.17
- IPG 0.11
- Stochastic Oscillator
- MEDP 58.00
- IPG 94.85
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.